A study published this week in the Journal of Clinical Oncology said that as much as 72 percent of the throat tumors in men may be linked to the human papillomavirus, known as HPV.
According to the report, researchers speculate that the virus spreads mainly through oral sex, and may already account for more cases of throat cancer than smoking.
Researchers examined 271 throat-tumor samples collected over 20 years ending in 2004 and found that the percentage of oral cancers linked to human papillomavirus or HPV, surged to 72 percent from about 16 percent, according released a report yesterday in the Journal of Clinical Oncology. By 2020, the virus-linked tumors throat - a largely male influence - will be more common than HPV-caused cervical cancer, the report found.
. . . Until recently, head and neck cancer occurred mainly in older patients and was associated with tobacco and alcohol use. The HPV-linked head and neck cancer, is usually the tonsils, palate or tongue, hit men to their 30s, 40s, and 50s, Gillison said. It is unclear why women are affected much less often than men, she said.
. . . In a 2007 study published in epidemiology New England Journal of Medicine, Gillison and her colleagues found that a high number of oral or vaginal sex partners are risk factors for throat cancer-associated HPV.
The HPV virus is known to cause cervical cancer, but the new study showed also that the HPV virus fueling a 28 percent rise in cancer cases orpharyngeal from 1988 - to 10,000 additional cases per year. If the trend continues, the type of throat cancer will surpass upper cervical cancer as the nation's most HPV-related cancers within 10 years.
"The burden of cancer causing HPV is to be transferred from women to men in this decade," said Maura Gillison, the oncologist at Ohio State University and lead author of the study. "What we believe is happening is that the number of sexual partners and increased exposure to HPV same time over the period."
As one of the currently approved vaccines to prevent cervical cancer (Gardasil and Cervarix, the market is Merck and GlaxoSmithKline, respectively) to target the HPV strain linked to oral cancer, but whether the results will recently put pressure on companies to conduct trials to examine their vaccines' ability to ward off HPV infections persist throat. Company says they are not any plans for any clinical trials at this time.
According to the report, researchers speculate that the virus spreads mainly through oral sex, and may already account for more cases of throat cancer than smoking.
Researchers examined 271 throat-tumor samples collected over 20 years ending in 2004 and found that the percentage of oral cancers linked to human papillomavirus or HPV, surged to 72 percent from about 16 percent, according released a report yesterday in the Journal of Clinical Oncology. By 2020, the virus-linked tumors throat - a largely male influence - will be more common than HPV-caused cervical cancer, the report found.
. . . Until recently, head and neck cancer occurred mainly in older patients and was associated with tobacco and alcohol use. The HPV-linked head and neck cancer, is usually the tonsils, palate or tongue, hit men to their 30s, 40s, and 50s, Gillison said. It is unclear why women are affected much less often than men, she said.
. . . In a 2007 study published in epidemiology New England Journal of Medicine, Gillison and her colleagues found that a high number of oral or vaginal sex partners are risk factors for throat cancer-associated HPV.
The HPV virus is known to cause cervical cancer, but the new study showed also that the HPV virus fueling a 28 percent rise in cancer cases orpharyngeal from 1988 - to 10,000 additional cases per year. If the trend continues, the type of throat cancer will surpass upper cervical cancer as the nation's most HPV-related cancers within 10 years.
"The burden of cancer causing HPV is to be transferred from women to men in this decade," said Maura Gillison, the oncologist at Ohio State University and lead author of the study. "What we believe is happening is that the number of sexual partners and increased exposure to HPV same time over the period."
As one of the currently approved vaccines to prevent cervical cancer (Gardasil and Cervarix, the market is Merck and GlaxoSmithKline, respectively) to target the HPV strain linked to oral cancer, but whether the results will recently put pressure on companies to conduct trials to examine their vaccines' ability to ward off HPV infections persist throat. Company says they are not any plans for any clinical trials at this time.
0 comments:
Post a Comment